基因多态性与铂类药物毒性反应研究进展  

Advances in relationship of genetic polymorphism with the toxicity caused by platinum-based therapy

作　　者：郑艺[1] 尹继业[1] 周宏灏[1] 刘昭前[1] 

机构地区：[1]中南大学湘雅医院临床药理研究所,中南大学临床药理研究所,遗传药理学湖南省重点实验室

出　　处：《中国临床药理学与治疗学》2014年第9期1051-1056,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家高技术研究发展计划(863计划)(2012AA02A517);国家自然科学基金(81173129;81373490);湖南省自然科学创新群体基金(12JJ7006)

摘　　要：铂类药物广泛应用于肺癌、大肠癌、卵巢癌、乳腺癌等多种癌症的治疗,取得显著疗效的同时也不可避免地给患者带来严重的毒副反应。临床研究发现,在化疗方案与用药剂量相同的情况下,铂类化疗导致的毒性具有较大的个体差异,而这种差异在一定程度上与个体遗传多态性相关。本文就铂类药物转运体、代谢酶、DNA损伤修复等相关基因多态与铂类药物化疗毒性之间的相关性作一综述。Platinum-based therapy are widely used in treating lots of cancers such as lung cancer, colorectal cancer, ovarian cancer and breast cancer. Although the efficacy of platinum drugs are quite notable in clinical practice, serious toxicity are inevitable. Clinical research have revealed that a wide inter-individual variability in the toxicity caused by Platinum-based therapy exists and this variability may partly due to individual genetic variations. This review summarizes the relationship between the polymorphisms of genes encoding platinum-based drug transporters, platinum-based drug-metabolizing enzymes and DNA repair enzymes and toxicity of platinum-based drugs.

关 键 词：药物基因组学 毒副反应 铂类药物 

分 类 号：R969.8[医药卫生—药理学]